UK markets closed

Bionano Genomics, Inc. (BNGO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.5300+0.0500 (+3.38%)
At close: 04:00PM EDT
1.5300 0.00 (0.00%)
After hours: 04:23PM EDT
Sign in to post a message.
  • Z
    Zach
    Bargain buying time for BNGO investors. CEO Erik H. and new sales force team is making progress with demonstrating the superior aspects of BNGO cutting edge Genomic Technology for everyday testing and research. BNGO life saving products are becoming a standard used globally. Sales/orders are growing. BNGO technology shows more deeper details at lower costs with faster results for patients. Buy&Hold 2022
  • G
    Georgio
    Nice upward momentum starting. BNGO is now getting reimbursed from insurance companies and does not need FDA approval as Sales indicate. BNGO now has insurance code assigned. Of course U.S. FDA approval will help with sales in U.S. but Hospitals/Clinics are already using BNGO Saphyr system genomic technology and the results faster, deeper detailed and less expensive too. Europe, Australia, China, South America, and U.S. Clinics & Hospitals are now using BNGO Genomic systems.......Buy & Hold 2022 it's a growth company
  • V
    VICTOR
    What's China got to do with it? announced the publication of an evaluation of OGM from The First Affiliated Hospital of Zhengzhou, the largest hospital in Central China, highlighting the utility of OGM for structural variant analysis, including in a workflow for preimplantation genetic testing.

    In this study, researchers, led by Dr. Xiangdong Kong, evaluated the use of OGM to detect chromosome balanced translocations and compared results to a variety of methods, including karyotype analysis, FISH, and CNV-seq. Balanced reciprocal translocations are one of the most common chromosomal abnormalities and may lead to infertility, recurrent pregnancy loss, or genetic defects. Analysis of this abnormality may be helpful in the screening and analysis of embryos prior to implantation, as part of fertility treatment. The paper suggests a need for new methods to complement existing analysis techniques, such as karyotype and FISH, which are described as time consuming and relatively low-resolution, and next generation sequencing (NGS) which can enable copy number variation (CNV) analyses at the whole genome level but cannot be used to detect chromosomal translocations or inversions. The authors demonstrated that OGM performed well in the analysis of these variants, which led them to suggest that OGM could be used as part of the workflow to detect chromosomal abnormalities at a higher resolution.

    “We believe this paper highlights the growing validation of OGM in different applications for clinical research in cytogenetics. The work by Dr. Kong and his team at Zhengzhou University further extends this validation and highlights the utility of OGM. Incorporating OGM data in the analysis of embryos prior to implantation is innovative and the approach could be part of a solution for recurrent pregnancy loss, which represents an area of unmet need globally,” Money Sales or Sales Money......
  • G
    Georgio
    BNGO new SEC filings show several InsiderBuys including CEO which has upped the stock ratings by analysts. BNGO growth stock 2022
  • j
    jarred
    Some famous investor said if you can’t be comfortable down 50% you shouldn’t invest.
    Wish people read more and typed less
  • B
    BNGO bull s
    Cant believe, is BNGO teally in green. Need to take a picture for memory this special moment.
  • J
    John
    Nasdaq green, Bingo red
    Classic
  • Z
    Zach
    A good day for BNGO inverstors options say over $2 and higher soon. BNGO A1+ Genomic technology is really getting noticed 2022 thanks to BNGO CEO mngt. beefing up sales force and academic acceptance growing Globally with hositals/institutios on all the Continents on planet earth.

    Strong Buy&Hold 2022
  • P
    Powerpc_marker2
    BNGO insiders are buying! Hold tight and will be rewarded in the end. Investment needs patience like Warren Buffet!
  • J
    Jeff
    Big caps still getting slammed tsla, wmt, aapl. BNGO maintaining above 1.60 losses are shifting away from life science stocks.
  • B
    BNGO bull s
    PACB replaced by BNGO. Great news and a sign that sales will increase by over100% year to year. Future is bright. Hold on your investmemt. Sure past was painful for everyone. But now we are starting to take off. Dont lose the moment.
  • J
    Jayson
    BNGO insiders just BOUGHT more shares this month May15th, May 16th & May 17th 2022 SEC filings show insiders buying more shares, that is always a good sign for future growth. I bought more shares also
    BNGO could go back over $10 again 2022 as sales grow

    It appears the dishonest shorts lying again......as usual
  • J
    John
    just picked up at $1.58, LETS GO!
  • w
    wscott
    These numbers suggest BNGO needs to grow martlet penetration much, much faster…facts that show vastly improved efficiency of Safire vs legacy systems will be necessary to create this growth, nothing else than a world beating product will be of importance…product will have to sell itself….BNGO margins and growth kind of suck vs ramped up costs and cash burn…still time, but it’s a tighter race the the management and analysts are acknowledging: “ Total revenue for Q1 2022 was $5.7 million, up 80% from Q1 2021.

    Gross margin for Q1 2022 was 15%, compared to 33% from Q1 2021. The decrease was primarily due to low yields on our chip consumables produced at one of our contract manufacturers. Gross margin improved over the fourth quarter of 2021 of 4%, primarily due to lower write-off of inventory.

    Q1 2022 GAAP operating expense was $30.8 million, compared to $12.2 million in Q1 2021. Q1 2022 non-GAAP1 operating expense was $24.3 million, compared to $11.8 million in Q1 2021. Q1 2022 non-GAAP operating expense excludes $5.1 million in stock-based compensation, and $1.4 million in amortization of intangibles. The year-over-year increase was primarily due to increased headcount-related spending, increased R&D expense, and increased marketing expenses.

    At March 31, 2022, the Company had cash, cash equivalents, and available-for-sale securities of $216.5 million.”
  • D
    Dale
    BNGO likely just quadrupled their market potential in China. Plus, it won't have to deal with all of the inefficient firewalls here in the U.S. ie. If it works, is faster, more accurate and less expensive, it will be embraced.
  • J
    Jeff
    When this market finally turns around most likely second half of this year this company will be racing ahead with earnings and higher work flow results.
  • S
    Sean m
    Easily my worst investment, oh well it's worth so little now no point in selling, it will sit in my portfolio for years as a constant reminder to put my money in good quality companies that make money so at least it has some value.
  • R
    Roman
    Just added some more shares at $1.57.
  • J
    Jeff
    Higher closing on bad market days I think our low of 1.16 is ancient history wish I would have picked up at that level.
  • e
    edmands
    I am staying far away from BNGO - It looks like it is going to drop off a cliff. I actually get way better stocks at (http://Themaxgains.tech)